Back

Metabolic modulation and cardioprotection by SGLT2 inhibitors canagliflozin and dapagliflozin: a novel strategy to balance antitumor efficacy and cardiotoxicity in HER2-positive breast cancer therapy

10 May 2026 (09:30 - 10:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity across the cancer journey: early detection, mechanisms, and protective strategies Cardio-Oncology Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
Evidence of cardiotoxic immune activation by triple immune checkpoint blockade: a translational alert for clinical surveillance in cancer patients
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Performance of cardiotoxicity risk scores in a tertiary center cardio-oncology clinic
Doctor D. Ferreira (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Clinical outcomes of transcatheter edge-to-edge mitral valve repair (M-TEER) in patients with and without cancer history: a systematic review and meta-analysis
Doctor K. Keramida (Athens, GR)
Abstract Slides
Presentation thumbnail
Real-World incidence and risk factors for osimertinib-associated cardiotoxicity
Doctor J. Fernandes Pedro (Lisbon, PT)
Abstract Slides

Access the full session

Session thumbnail
Cardiotoxicity across the cancer journey: early detection, mechanisms, and protective strategies

The Event

Event poster

Heart Failure 2026

10 May 2026 09:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources